BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/22/2022 9:25:37 AM | Browse: 490 | Download: 950
 |
Received |
|
2021-03-18 01:39 |
|
Peer-Review Started |
|
2021-03-18 02:14 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-07-18 05:06 |
|
Revised |
|
2021-08-22 15:06 |
|
Second Decision |
|
2022-01-24 03:56 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2022-01-25 03:26 |
|
Articles in Press |
|
2022-01-25 03:26 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-02-15 09:28 |
|
Publish the Manuscript Online |
|
2022-02-22 09:25 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Hepatocellular carcinoma in patients with metabolic dysfunction-associated fatty liver disease: Can we stratify at-risk populations?
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Eduardo Fassio, Fernando J Barreyro, M Soledad Pérez, Diana Dávila, Graciela Landeira, Gisela Gualano and Gabriela Ruffillo |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Eduardo Fassio, MD, Hepatology Section, Gastroenterology Service, Hospital Nacional Prof. Alejandro Posadas, Av. Presidente Illia y Marconi, s/n, El Palomar 1684, Buenos Aires, Argentina. efassio@intramed.net |
| Key Words |
Hepatocellular carcinoma; Metabolic dysfunction-associated fatty liver disease; Nonalcoholic fatty liver disease; Surveillance for hepatocellular carcinoma; Incidence of hepatocellular carcinoma; Nonalcoholic steatohepatitis |
| Core Tip |
Metabolic dysfunction-associated fatty liver disease (MAFLD) affects 25% of general population worldwide. Within that huge number of patients, a minority will progress to cirrhosis, with an annual incidence rate of hepatocellular carcinoma (HCC) > 1%. In them, surveillance for HCC by means of ultrasound with or without alpha-fetoprotein measurement is cost-effective. In patients with MAFLD cirrhosis who are men, older and diabetic, risk is even higher and magnetic resonance imaging might be a better screening test. However, the great challenge is stratifying the HCC risk in patients with MAFLD without cirrhosis. Factors that can help to stratify their risk (genetic, demographic, metabolic, non-invasive fibrosis tests) will be reviewed. |
| Publish Date |
2022-02-22 09:25 |
| Citation |
Fassio E, Barreyro FJ, Pérez MS, Dávila D, Landeira G, Gualano G, Ruffillo G. Hepatocellular carcinoma in patients with metabolic dysfunction-associated fatty liver disease: Can we stratify at-risk populations? World J Hepatol 2022; 14(2): 354-371 |
| URL |
https://www.wjgnet.com/1948-5182/full/v14/i2/354.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v14.i2.354 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
